摩根大通解密BD潮：巨头“抄底”中国创新药，下一个爆款在哪？

Core Insights - The global biopharmaceutical innovation landscape, traditionally dominated by multinational corporations (MNCs), is undergoing significant structural changes, with China's innovative drug industry emerging as a key player on the global stage [1] - China's transition from a "fast follower" to a "first mover" in innovative drugs is becoming an irreversible trend, as highlighted by The Economist, indicating that Chinese innovation drugs are at a "critical point" of globalization [1] - Data shows that China's share in global clinical trials and licensing transactions is rising significantly, with Chinese biotech companies' stock prices outperforming their U.S. counterparts over the past year [1][2] - The total market capitalization of Chinese listed biotech companies is still less than 15% of their U.S. peers, presenting a "historic investment opportunity" as perceived by international capital [1] Group 1 - The cost-effectiveness and speed advantages of Chinese innovative drug companies are notable, with drug discovery phases being 2-3 times faster and patient recruitment in clinical trials being 2-5 times quicker than international counterparts [4] - The total amount of licensing transactions for Chinese innovative drugs is expected to exceed $100 billion by 2025, with significant deals already occurring, such as the $12.5 billion upfront payment from Pfizer to 3SBio [4][2] - The surge in business development (BD) activities reflects a growing interest from MNCs in China's innovative drug capabilities, particularly in advanced fields like T-cell engagers and CAR-T therapies [2][5] Group 2 - The market is witnessing a "BD frenzy," with MNCs actively engaging in acquisitions, driven by the recognition of China's improving innovation, research, and clinical capabilities [5][6] - The anticipated growth in the pharmaceutical industry is expected to lead to a significant increase in the Hang Seng Index, with projections indicating a potential doubling by 2025 [8] - The overall revenue of Chinese innovative drug companies reached 48.83 billion yuan in the first three quarters of 2025, marking a 22% year-on-year increase, with the sector achieving its first quarterly profit since inception [8] Group 3 - The shift in capital market dynamics is evident, with investors now focusing more on the "hard power" of companies rather than just their narrative or story [10][9] - The trend of companies transitioning from A-share to Hong Kong markets is gaining momentum, with a growing number of firms seeking to list in Hong Kong, reflecting a tightening scrutiny of fundamentals by investors [11][14] - The current market environment is characterized by a rational return, where investors prioritize solid fundamentals over speculative narratives, indicating a more cautious approach to investment [12][13]